ECOR
electroCore, Inc.
Healthcare — Medical Devices
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Price History
Fundamentals
| Market Cap | $54.86M |
| P/E Ratio (TTM) | - |
| Forward P/E | -11.06 |
| EPS (TTM) | $-1.77 |
| Dividend Yield | - |
| Profit Margin | -44.08% |
| Revenue Growth | 42.60% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $19.57 |
| Analysts | 5 |
| Next Earnings | Aug 6, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 40.4 |
| Beta | 0.89 |
| SMA 20 | $6.41 |
| SMA 40 | $7.61 |
| 52-Week High | $10.50 |
| 52-Week Low | $4.16 |
| 50-Day Avg | $7.80 |
| 200-Day Avg | $6.37 |
| Avg Volume | 109.8K |
| Volume | 37.1K |
Performance Analysis
NEUTRALECOR presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Aug 01, 2026 04:12 UTC
Back to Screener Export Report